Publication | Closed Access

Pembrolizumab plus chemotherapy as neoadjuvant treatment of high-risk, early-stage triple-negative breast cancer: results from the phase 1b open-label, multicohort KEYNOTE-173 study

Phase 1BBreast OncologyOncologyPathologyNeoadjuvant TreatmentKeynote-173 StudyImmune Checkpoint InhibitorBreast CancerCancer TreatmentMedicineRadiation OncologyMolecular Oncology